Want to see IL:PPBT full AI Analyst Report?
Total Valuation
Purple Biotech has a market cap or net worth of ₪32.37M. The enterprise value is -3.60M.
Market Cap₪32.37M
Enterprise Value-3.60M
Share Statistics
Purple Biotech has 3,236,517,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,236,517,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Purple Biotech’s return on equity (ROE) is -2.72 and return on invested capital (ROIC) is -272.81%.
Return on Equity (ROE)-2.72
Return on Assets (ROA)-1.50
Return on Invested Capital (ROIC)-272.81%
Return on Capital Employed (ROCE)-2.80
Revenue Per Employee0.00
Profits Per Employee-2.65M
Employee Count10
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Purple Biotech is ―. Purple Biotech’s PEG ratio is -0.00363.
PE Ratio―
PS Ratio0.00
PB Ratio0.37
Price to Fair Value0.37
Price to FCF-0.61
Price to Operating Cash Flow-0.92
PEG Ratio-0.00363
Income Statement
In the last 12 months, Purple Biotech had revenue of 0.00 and earned -26.39M in profits. Earnings per share was -0.03.
Revenue0.00
Gross Profit-219.74K
Operating Income-27.46M
Pretax Income-26.49M
Net Income-26.39M
EBITDA-26.25M
Earnings Per Share (EPS)-0.03
Cash Flow
In the last 12 months, operating cash flow was -6.64M and capital expenditures 2.03M, giving a free cash flow of -6.75M billion.
Operating Cash Flow-6.64M
Free Cash Flow-6.75M
Free Cash Flow per Share>-0.01
Dividends & Yields
Purple Biotech pays an annual dividend of 249.549, resulting in a dividend yield of ―
Dividend Per Share249.549
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.12
52-Week Price Change-77.78%
50-Day Moving Average1.00
200-Day Moving Average1.08
Relative Strength Index (RSI)40.92
Average Volume (3m)8.90M
Important Dates
Purple Biotech upcoming earnings date is Jul 30, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Purple Biotech as a current ratio of 1.27, with Debt / Equity ratio of 1.87%
Current Ratio1.27
Quick Ratio1.27
Debt to Market Cap0.00
Net Debt to EBITDA0.32
Interest Coverage Ratio-25.83
Taxes
In the past 12 months, Purple Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Purple Biotech EV to EBITDA ratio is 0.19, with an EV/FCF ratio of 0.82.
EV to Sales0.00
EV to EBITDA0.19
EV to Free Cash Flow0.82
EV to Operating Cash Flow0.82
Balance Sheet
Purple Biotech has ₪6.49M in cash and marketable securities with ₪184.00K in debt, giving a net cash position of ₪6.30M billion.
Cash & Marketable Securities₪6.49M
Total Debt₪184.00K
Net Cash₪6.30M
Net Cash Per Share<₪0.01
Tangible Book Value Per Share<₪0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Purple Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-17.14%